Skip to main navigation Skip to search Skip to main content

A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 Monohydrate in the Acute Treatment of Patients with DSM-IV-TR Schizophrenia - protocol H8Y-MC-HBBN

Project: Research

Project Details

StatusFinished
Effective start/end date04/1/11 → 09/30/13

Funding

  • Eli Lilly and Company: $43,651.18